Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease

Basit Öğe Kaydı
dc.contributor.authorLiabeuf, Sophie
dc.contributor.authorHafez, Gaye
dc.contributor.authorPesic, Vesna
dc.contributor.authorSpasovski, Goce
dc.contributor.authorBobot, Mickael
dc.contributor.authorMaciulaitis, Romaldas
dc.contributor.authorBumblyte, Inga Arune
dc.contributor.authorFerreira, Ana Carina
dc.contributor.authorFarinha, Ana
dc.contributor.authorMalyszko, Jolanta
dc.contributor.authorPepin, Marion
dc.contributor.authorMassy, Ziad A.
dc.contributor.authorUnwin, Robert
dc.contributor.authorCapasso, Giovambattista
dc.contributor.authorMani, Laila-Yasmin
dc.contributor.authorCONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)
dc.date.accessioned2024-08-13T10:42:27Z
dc.date.available2024-08-13T10:42:27Z
dc.date.issued2024en_US
dc.departmentFakülteler, Eczacılık Meslek Bilimleri Bölümü, Farmakoloji Ana Bilim Dalıen_US
dc.description.abstractThe relationship between chronic kidney disease (CKD) and cognitive function has received increased attention in recent years. Antibacterial agents (ABs) represent a critical component of therapy regimens in patients with CKD due to increased susceptibility to infections. Following our reviewing work on the neurocognitive impact of long-term medications in patients with CKD, we propose to focus on AB-induced direct and indirect consequences on cognitive function. Patients with CKD are predisposed to adverse drug reactions (ADRs) due to altered drug pharmacokinetics, glomerular filtration decline, and the potential disruption of the blood-brain barrier. ABs have been identified as a major cause of ADRs in vulnerable patient populations. This review examines the direct neurotoxic effects of AB classes (e.g. beta-lactams, fluoroquinolones, aminoglycosides, and metronidazole) on the central nervous system (CNS) in patients with CKD. We will mainly focus on the acute effects on the CNS associated with AB since they are the most extensively studied effects in CKD patients. Moreover, the review describes the modulation of the gut microbiota by ABs, potentially influencing CNS symptoms. The intricate brain-gut-kidney axis emerges as a pivotal focus, revealing the interplay between microbiota alterations induced by ABs and CNS manifestations in patients with CKD. The prevalence of antibiotic-associated encephalopathy in patients with CKD undergoing intravenous AB therapy supports the use of therapeutic drug monitoring for ABs to reduce the number and seriousness of ADRs in this patient population. In conclusion, elucidating AB-induced cognitive effects in patients with CKD demands a comprehensive understanding and tailored therapeutic strategies that account for altered pharmacokinetics and the brain-gut-kidney axis.en_US
dc.identifier.citationLiabeuf, S., Hafez, G., Pesic, V., Spasovski, G., Bobot, M., Maciulaitis, R., Bumblyte, I. A., Ferreira, A. C., Farinha, A., Malyszko, J., Pepin, M., Massy, Z. A., Unwin, R., Capasso, G., Mani, L.-Y., CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). (2024). Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease. Clinical Kidney Journal, 17(8). 10.1093/ckj/sfae174en_US
dc.identifier.issn2048-8505
dc.identifier.issn2048-8513
dc.identifier.issue8en_US
dc.identifier.scopus2-s2.0-85200854899
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://hdl.handle.net/20.500.12939/4804
dc.identifier.volume17en_US
dc.identifier.wosWOS:001386365000001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorHafez, ulty of Pharmacy, Altinbas Univ
dc.language.isoen
dc.relation.ispartofClinical Kidney Journal
dc.relation.isversionof10.1093/ckj/sfae174en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdverse drug reactionsen_US
dc.subjectAntibacterial agentsen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectCognitive impairmenten_US
dc.subjectDrugsen_US
dc.titleDrugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
sfae174.pdf
Boyut:
2.2 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu